German GKV law substantially tightens patent-medicine pricing controls

Germany has enacted the Statutory Health Insurance Contribution Rate Stabilisation Act (GKV-Beitragssatzstabilisierungsgesetz, GKV-BStabG), after Parliament substantially tightened the pharmaceutical settlement contained in the April cabinet draft. The Bundestag and Bundesrat completed passage on 10 July. The law was published in the Federal Law Gazette on 29 July and entered into force on 30 July, although several pharmaceutical provisions apply from 1 January 2027.

The most significant parliamentary change concerns the manufacturer rebate. The draft’s variable rebate has been replaced by a permanent additional 8.5% rebate from January 2027, taking the statutory total to 15.5% for most patent-protected medicines. Exemptions include fixed-reference-price medicines, biosimilars and their reference products, certain supply-critical off-patent medicines and reserve antibiotics. The additional rebate may also be replaced where an AMNOG reimbursement agreement explicitly provides for this.

Patent-protected vaccines face a separate additional rebate of 9%, alongside a price moratorium from January 2027 to the end of 2030.

The law also creates a new competitive mechanism for patent-protected medicines. Sickness funds may group therapeutically comparable products and conclude exclusive rebate contracts across different active substances. Until the end of 2030, this is restricted to JAK inhibitors, CGRP antagonists, PARP inhibitors, PCSK9 inhibitors and PD-1/PD-L1 inhibitors. Prescribers must normally use contracted medicines unless individual medical reasons justify another choice. Contracted products will also receive favourable treatment in prescribing-efficiency reviews.

Price-volume control under the Pharmaceuticals Market Reorganisation Act (Arzneimittelmarktneuordnungsgesetz, AMNOG) becomes more prescriptive. Reimbursement agreements must address volume, and where the parties fail to agree a mechanism, a statutory formula applies annually from the fourth year after launch. The formula reflects both expenditure growth and absolute expenditure. Parliament increased the latter component from 1% in the cabinet draft to 1.5%. Existing reimbursement agreements and arbitration decisions concluded before 30 July may be terminated by either party until 1 October 2026 and reopened under the new framework.

The legislation also removes two controls introduced in 2022. It abolishes the AMNOG ‘guardrails’ that restricted reimbursement-price negotiations according to added benefit and comparator costs, and removes the 20% discount previously applied to specified combinations of medicines with new active substances. These changes restore greater negotiation flexibility in individual AMNOG cases, while the new rebate and price-volume provisions apply broader expenditure controls across the patent-protected market.

A further exemption links pricing directly to clinical research activity in Germany. New active substances first marketed from 2027 can receive a renewable three-year exemption from the additional 8.5% rebate where at least 5% of participants in the relevant company-sponsored clinical trials were enrolled at German sites. Applications will be assessed by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM).

The final settlement therefore changes several parts of the commercial environment simultaneously. It increases baseline net-price pressure, gives sickness funds a new route to create competition before patent expiry and makes volume growth a more automatic determinant of reimbursement prices. At the same time, removal of the AMNOG guardrails and combination discount restores some negotiating flexibility. The clinical-trial exemption adds an explicit link between pharmaceutical pricing and German research investment.

Source: Federal Ministry of Health, BMG
Link: Bundestag beschließt GKV-Beitragssatzstabilisierungsgesetz (Bundestag adopts the GKV Contribution Rate Stabilisation Act)
Date: 10 July 2026

Source: Federal Ministry of Health, BMG
Link: GKV-Beitragssatzstabilisierungsgesetz (GKV Contribution Rate Stabilisation Act)
Date: 29 July 2026

Source: Association of Research-Based Pharmaceutical Companies, vfa
Link: Bundestag beschließt BStabG: Kurzfristige Kassenentlastung schwächt verlässliche Versorgung von Patient:innen in Deutschland (Bundestag adopts BStabG: short-term health insurance relief weakens reliable patient care in Germany)
Date: 10 July 2026